Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from emtricitabine + nevirapine + tenofovir to rilpivirine + emtricitabine + tenofovir in virologically suppressed HIV-1 patients
2012-001142-18Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by Erasmus MC. Primary endpoint: Virologic suppression at week 12 post-switch. Started Aug 2012; status: active.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2012-001142-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001142-18.